Maat Pharma SA
Research Maat Pharma SA (MAAT) on Bullrun: market cap EUR 60.11M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMAAT
- ExchangePA
- CountryFrance
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 60.11M
- Financial periodFY2025
- RevenueEUR 4.52M
- Revenue growth40.7%
- Net income-EUR 31.06M
- Free cash flow-EUR 16.33M
- Gross margin69.1%
Valuation Snapshot
latest market cap is EUR 60.11M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 4.52M | -EUR 31.06M | -EUR 16.33M | 69.1% | -1.9 | EUR 24.87M | EUR 15.40M | EUR 1.80M |
| FY2024 | EUR 3.22M | -EUR 28.90M | -EUR 22.79M | 61.1% | -2.2 | EUR 20.15M | EUR 15.96M | EUR 10.34M |
| FY2023 | EUR 2.23M | -EUR 19.72M | -EUR 19.76M | 74.3% | -1.7 | EUR 24.28M | EUR 14.07M | EUR 20.47M |
| FY2022 | EUR 1.43M | -EUR 13.71M | -EUR 13.27M | 76.3% | -1.4 | EUR 35.25M | EUR 11.36M | EUR 26.81M |
| FY2021 | EUR 972.00K | -EUR 9.02M | -EUR 8.17M | 82.9% | -3.7 | EUR 43.31M | EUR 5.81M | EUR 39.86M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-23 | EUR 60.11M | n/a | n/a | n/a |
About Maat Pharma SA
MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in pivotal phase 3 clinical trial for the treatment of acute graft versus host diseases with gastrointestinal involvement; MaaT033, which is in phase 2b clinical trial for the improvement of survival at 12 months for patients with blood cancer receiving allogenic hematopoietic stem cell transplantation;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Maat Pharma SA's market cap?
Maat Pharma SA's market capitalization is EUR 60.11M.
What does Maat Pharma SA do?
MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival.